Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)
Maxcyte's (MXCT) quarterly Non-Current Deffered Revenue came in at $344600.0 in Q3 2022, down 23.46% on a QoQ basis from $450200.0 in Q4 2021.
Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Maxcyte (MXCT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $344600.0 in Q3 2022.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $344600.0 in Q3 2022; TTM through Sep 2022 was $344600.0, a N/A change from a year earlier, with the FY2021 full-year figure at $450200.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $344600.0, down from $450200.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for MXCT reached as high as $450200.0 in Q4 2021 and fell as low as $344600.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 512.79 Mn |
| 10 | Maxcyte | 110.62 Mn | 110.62 Mn | 8.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 344,600.00 |
| Dec 31, 2021 | 450,200.00 |